ORAL ESCALATING DOSE OF CYCLOSPORINE-A COMBINED WITH 4-EPIDOXORUBICIN IN ADVANCED COLORECTAL-CANCER - A PHASE-I STUDY

  • Authors:
    • S CASCINU
    • E DELFERRO
    • C GRIANTI
    • A FEDELI
    • G CATALANO
  • View Affiliations

  • Published online on: November 1, 1995     https://doi.org/10.3892/or.2.6.1033
  • Pages: 1033-1035
Metrics: Total Views: 0 (Spandidos Publications: | PMC Statistics: )
Total PDF Downloads: 0 (Spandidos Publications: | PMC Statistics: )


Abstract

Multidrug resistance, a major factor in the resistance to drugs, can be reversed by cyclosporin A. It is generally given by intravenous route. The aim of the present study was to assess the possibility of achieving useful plasma levels, giving cyclosporin A orally in advanced colorectal cancer patients treated with 4-epidoxorubicin. Cyclosporin A was given orally twice a day, for four days. The starting study dose was 5 mg/kg. Dose in cohorts of 3 patients was escalated to 10, 15, 20, 30, 40 mg/kg if the previous dose was not able to determine the target blood level (2,000 ng/ml). Cyclosporin A blood levels were analyzed by a specific fluorescence polarization immunoassay method (TDx; Abbot Laboratoires, North Chigaco, IL). 4-epidoxorubicin was given at a fixed dose of 75 mg/m(2), every 3 weeks. None of the dose levels of cyclosporin A given orally produced the target blood level. Only two patients, receiving cyclosporin at a dose of 30 mg/kg, and two after a CsA dose of 40 mg/kg, presented blood levels higher than 1,000 ng/ml, but however, lower than 1,500 ng/ml. In conclusion, the oral route of administration of cyclosporin does not seem recommendable in order to reverse multidrug resistance because it is not able to produce sufficient plasma levels.

Related Articles

Journal Cover

November 1995
Volume 2 Issue 6

Print ISSN: 1021-335X
Online ISSN:1791-2431

Sign up for eToc alerts

Recommend to Library

Copy and paste a formatted citation
x
Spandidos Publications style
CASCINU S, DELFERRO E, GRIANTI C, FEDELI A and CATALANO G: ORAL ESCALATING DOSE OF CYCLOSPORINE-A COMBINED WITH 4-EPIDOXORUBICIN IN ADVANCED COLORECTAL-CANCER - A PHASE-I STUDY. Oncol Rep 2: 1033-1035, 1995
APA
CASCINU, S., DELFERRO, E., GRIANTI, C., FEDELI, A., & CATALANO, G. (1995). ORAL ESCALATING DOSE OF CYCLOSPORINE-A COMBINED WITH 4-EPIDOXORUBICIN IN ADVANCED COLORECTAL-CANCER - A PHASE-I STUDY. Oncology Reports, 2, 1033-1035. https://doi.org/10.3892/or.2.6.1033
MLA
CASCINU, S., DELFERRO, E., GRIANTI, C., FEDELI, A., CATALANO, G."ORAL ESCALATING DOSE OF CYCLOSPORINE-A COMBINED WITH 4-EPIDOXORUBICIN IN ADVANCED COLORECTAL-CANCER - A PHASE-I STUDY". Oncology Reports 2.6 (1995): 1033-1035.
Chicago
CASCINU, S., DELFERRO, E., GRIANTI, C., FEDELI, A., CATALANO, G."ORAL ESCALATING DOSE OF CYCLOSPORINE-A COMBINED WITH 4-EPIDOXORUBICIN IN ADVANCED COLORECTAL-CANCER - A PHASE-I STUDY". Oncology Reports 2, no. 6 (1995): 1033-1035. https://doi.org/10.3892/or.2.6.1033